[{"id":11090,"run_id":428,"as_of":"2026-09-08","ticker":"INBX","company":"Inhibrx Biosciences, Inc.","source":"weekly","conviction":50.4,"technical":56.8,"stage":"Mature Trend","gated":true,"n_gates":1,"gates":["Overlapping range behaviour — efficiency ratio 0.13 vs the 0.15 threshold (borderline, watch for resolution)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":114.34,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":17.0,"Volatility behaviour":5.5,"Cross-asset confirmation":13.3,"Sponsorship / positioning":9.6,"Catalyst alignment (insider)":5.0},"total_cfo_value":0.0,"total_other_value":2645399.0,"n_cfo_buys":0.0,"n_other_buys":1.0,"has_cfo_buy":false,"roles_buying":"1 CEO","npr":1.0,"cluster_insiders":1.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-09-08T21:26:21.132888+00:00"},{"id":11675,"run_id":433,"as_of":"2026-09-09","ticker":"INBX","company":"Inhibrx Biosciences, Inc.","source":"weekly","conviction":57.0,"technical":56.9,"stage":"Mature Trend","gated":true,"n_gates":1,"gates":["Overlapping range behaviour — efficiency ratio 0.13 vs the 0.15 threshold (borderline, watch for resolution)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":112.86,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":17.0,"Volatility behaviour":5.5,"Cross-asset confirmation":13.7,"Sponsorship / positioning":9.3,"Catalyst alignment (insider)":11.5},"total_cfo_value":0.0,"total_other_value":3499596.0,"n_cfo_buys":0.0,"n_other_buys":3.0,"has_cfo_buy":false,"roles_buying":"1 CEO, 2 Director","npr":1.0,"cluster_insiders":3.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-09-09T20:56:28.992589+00:00"},{"id":12277,"run_id":437,"as_of":"2026-09-10","ticker":"INBX","company":"Inhibrx Biosciences, Inc.","source":"weekly","conviction":56.7,"technical":56.5,"stage":"Mature Trend","gated":true,"n_gates":1,"gates":["Overlapping range behaviour — efficiency ratio 0.11 vs the 0.15 threshold (borderline, watch for resolution)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":111.42,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":17.0,"Volatility behaviour":5.5,"Cross-asset confirmation":13.8,"Sponsorship / positioning":8.9,"Catalyst alignment (insider)":11.5},"total_cfo_value":0.0,"total_other_value":3499596.0,"n_cfo_buys":0.0,"n_other_buys":3.0,"has_cfo_buy":false,"roles_buying":"1 CEO, 2 Director","npr":1.0,"cluster_insiders":3.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-09-10T21:40:45.725805+00:00"},{"id":12385,"run_id":438,"as_of":"2026-09-11","ticker":"INBX","company":"Inhibrx Biosciences, Inc.","source":"weekly","conviction":55.8,"technical":55.4,"stage":"Mature Trend","gated":true,"n_gates":1,"gates":["Overlapping range behaviour — efficiency ratio 0.10 vs the 0.15 threshold (violent whipsaw, not a quiet range — the last pullback was 44% deep. Huge travel, no net progress)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":109.27,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":17.0,"Volatility behaviour":5.5,"Cross-asset confirmation":13.3,"Sponsorship / positioning":8.5,"Catalyst alignment (insider)":11.5},"total_cfo_value":0.0,"total_other_value":3499596.0,"n_cfo_buys":0.0,"n_other_buys":3.0,"has_cfo_buy":false,"roles_buying":"1 CEO, 2 Director","npr":0.9361184200335042,"cluster_insiders":3.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-09-11T21:13:17.292546+00:00"},{"id":12965,"run_id":440,"as_of":"2026-09-14","ticker":"INBX","company":"Inhibrx Biosciences, Inc.","source":"weekly","conviction":56.4,"technical":56.1,"stage":"Mature Trend","gated":true,"n_gates":1,"gates":["Overlapping range behaviour — efficiency ratio 0.10 vs the 0.15 threshold (violent whipsaw, not a quiet range — the last pullback was 44% deep. Huge travel, no net progress)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":110.47,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":17.0,"Volatility behaviour":5.5,"Cross-asset confirmation":14.1,"Sponsorship / positioning":8.3,"Catalyst alignment (insider)":11.5},"total_cfo_value":0.0,"total_other_value":3499596.0,"n_cfo_buys":0.0,"n_other_buys":3.0,"has_cfo_buy":false,"roles_buying":"1 CEO, 2 Director","npr":0.9361184200335042,"cluster_insiders":3.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-09-14T21:02:09.279670+00:00"},{"id":13576,"run_id":442,"as_of":"2026-09-15","ticker":"INBX","company":"Inhibrx Biosciences, Inc.","source":"weekly","conviction":56.5,"technical":56.2,"stage":"Mature Trend","gated":true,"n_gates":1,"gates":["Overlapping range behaviour — efficiency ratio 0.08 vs the 0.15 threshold (violent whipsaw, not a quiet range — the last pullback was 41% deep. Huge travel, no net progress)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":105.61,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":17.0,"Volatility behaviour":5.5,"Cross-asset confirmation":14.5,"Sponsorship / positioning":8.0,"Catalyst alignment (insider)":11.5},"total_cfo_value":0.0,"total_other_value":3499596.0,"n_cfo_buys":0.0,"n_other_buys":3.0,"has_cfo_buy":false,"roles_buying":"1 CEO, 2 Director","npr":0.9361184200335042,"cluster_insiders":3.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-09-15T21:04:48.311557+00:00"},{"id":14177,"run_id":444,"as_of":"2026-09-16","ticker":"INBX","company":"Inhibrx Biosciences, Inc.","source":"weekly","conviction":57.0,"technical":56.9,"stage":"Mature Trend","gated":true,"n_gates":1,"gates":["Overlapping range behaviour — efficiency ratio 0.05 vs the 0.15 threshold (violent whipsaw, not a quiet range — the last pullback was 41% deep. Huge travel, no net progress)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":101.77,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":17.0,"Volatility behaviour":5.5,"Cross-asset confirmation":15.4,"Sponsorship / positioning":7.6,"Catalyst alignment (insider)":11.5},"total_cfo_value":0.0,"total_other_value":3499596.0,"n_cfo_buys":0.0,"n_other_buys":3.0,"has_cfo_buy":false,"roles_buying":"1 CEO, 2 Director","npr":0.8523207097218631,"cluster_insiders":3.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-09-16T21:30:15.198638+00:00"},{"id":14771,"run_id":451,"as_of":"2026-09-17","ticker":"INBX","company":"Inhibrx Biosciences, Inc.","source":"weekly","conviction":62.4,"technical":63.6,"stage":"Mature Trend","gated":true,"n_gates":1,"gates":["Overlapping range behaviour — efficiency ratio 0.07 vs the 0.15 threshold (violent whipsaw, not a quiet range — the last pullback was 38% deep. Huge travel, no net progress)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":104.73,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":17.0,"Volatility behaviour":5.5,"Cross-asset confirmation":15.2,"Sponsorship / positioning":13.2,"Catalyst alignment (insider)":11.5},"total_cfo_value":0.0,"total_other_value":3499596.0,"n_cfo_buys":0.0,"n_other_buys":3.0,"has_cfo_buy":false,"roles_buying":"1 CEO, 2 Director","npr":0.8523207097218631,"cluster_insiders":3.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-09-17T21:06:22.295534+00:00"},{"id":15437,"run_id":456,"as_of":"2026-10-15","ticker":"INBX","company":"Inhibrx Biosciences, Inc.","source":"weekly","conviction":52.5,"technical":51.2,"stage":"No Long Regime","gated":true,"n_gates":2,"gates":["Price below the 200DMA — no long regime.","Overlapping range behaviour — efficiency ratio 0.03 vs the 0.15 threshold (violent whipsaw, not a quiet range — the last pullback was 33% deep. Huge travel, no net progress)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":90.5,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":10.5,"Volatility behaviour":9.5,"Cross-asset confirmation":14.0,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":11.5},"total_cfo_value":0.0,"total_other_value":6347357.0,"n_cfo_buys":0.0,"n_other_buys":7.0,"has_cfo_buy":false,"roles_buying":"3 CEO, 4 Director","npr":0.9157876532061002,"cluster_insiders":3.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-10-15T21:13:44.615367+00:00"},{"id":16029,"run_id":458,"as_of":"2026-10-16","ticker":"INBX","company":"Inhibrx Biosciences, Inc.","source":"weekly","conviction":52.5,"technical":51.2,"stage":"No Long Regime","gated":true,"n_gates":2,"gates":["Price below the 200DMA — no long regime.","Overlapping range behaviour — efficiency ratio 0.03 vs the 0.15 threshold (violent whipsaw, not a quiet range — the last pullback was 33% deep. Huge travel, no net progress)."],"sizing_low":0.0,"sizing_high":0.0,"sizing_label":"No trade / watch only","close":89.83,"sector":"Healthcare","etf":"XLV","pillars":{"Regime clarity":10.5,"Volatility behaviour":9.5,"Cross-asset confirmation":14.0,"Sponsorship / positioning":7.0,"Catalyst alignment (insider)":11.5},"total_cfo_value":0.0,"total_other_value":6347357.0,"n_cfo_buys":0.0,"n_other_buys":7.0,"has_cfo_buy":false,"roles_buying":"3 CEO, 4 Director","npr":0.9157876532061002,"cluster_insiders":3.0,"days_since_buy":null,"insider_lookup_failed":false,"technical_only":false,"created_at":"2026-10-16T20:55:56.165619+00:00"}]